FDA launches real-time clinical trial data pilot with AstraZeneca and Amgen

FDA launched a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to data as it flows in. AstraZeneca and Amgen are the initial pharma partners in the program focused on cancer drugs.

Clinical operations leaders should track this pilot's impact on submission timelines and data requirements. Contact your FDA liaison to understand how real-time data sharing might affect your current trial protocols.

NVIDIA introduced context parallelism in BioNeMo to handle biomolecular modeling tasks that exceed single GPU memory capacity. The approach addresses computational biology's historical memory constraints for complex biological systems.

Computational biology teams should evaluate whether your current protein folding or drug discovery workloads hit GPU memory limits. Request a BioNeMo demo if you're running multi-GPU NVIDIA infrastructure.

Boehringer Ingelheim's survodutide achieved weight loss results that Wall Street analysts called "Wegovy-like" in Phase 3 trials. The dual-acting drug also showed signs of preserving muscle mass during weight loss.

Endocrinology department heads should review your current obesity treatment protocols for muscle mass monitoring. Prepare for potential formulary discussions if survodutide reaches market with muscle preservation claims.